Document is current
Any future updates will be listed below
-
Authors
Abrams, Elissa M.
Alqurashi, Waleed
Fischer, David A.
Vander Leek, Timothy K.
Ellis, Anne K.
- License Information
-
More Information
Article History
Received: 12 September 2024
Accepted: 13 November 2024
First Online: 9 December 2024
Declarations
:
: Ethics approval and consent to participate are not applicable to this review article.
: Not applicable.
: Dr Elissa M. Abrams is an employee of Public Health Agency of Canada (PHAC); views expressed are her own and not those of PHAC. She is Section Head for Anaphylaxis/Food Allergy, and a Member of the Canadian Society of Allergy and Clinical Immunology (CSACI). Dr. Waleed Alqurashi has received grant funding from the Canadian Institute for Health Research. Dr. David A. Fischer is a previous President of the Canadian Society of Allergy & Clinical Immunology (CSACI). He has received consulting fees and honoraria for continuing education from AstraZeneca, GSK, Bausch Health, Valeo, AbbVie, Takeda, ALK, Pfizer, Aralez, Merck, Novartis, Sanofi, Pediapharm and Teva Pharmaceuticals. Dr. Timothy K. Vander Leek has participated in advisory boards and has received consulting fees and honoraria from Aralez/Miravo, Bausch Health, and Covis Pharma. Dr. Anne K. Ellis has participated in advisory boards for ALK-Abello, AstraZeneca, Bausch Health, LEO Pharma, Miravo, Merck, Novartis, has been a speaker for ALK-Abello, AstraZeneca, Bausch, Miravo, Medexus, Mylan, Novartis, Pfizer, Sanofi, StallergenesGreer and Regeneron. Her institution has received research grants from ALK Abello, Aralez, AstraZeneca, Bayer LLC, Medexus, Novartis, Sanofi and Regeneron. She has also served as an independent consultant to Bayer LLC, Pharming, and Regeneron.
: This article has been published as part of Allergy, Asthma & Clinical Immunology, Volume 20 Supplement 03, 2024: Practical Guide for Allergy and Immunology in Canada 2024. The full contents of the supplement are available at .
